去纤苷(去纤维钠)是什么药？

(also called defibrinated sodium) is a single-chain sodium salt of polydeoxyribose ribonuclease, which has anti-thrombotic, anti-ischemic, anti-inflammatory and fibrinolytic properties. Defibrotide is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects. Today let’s take a closer look at what kind of medicine is defibrotide?

Defibrotide is the first drug approved by the U.S. FDA to treat severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic venous obstruction (VOD) who have undergone blood or bone marrow hematopoietic stem cell transplantation (HSCT) and are accompanied by renal or lung function abnormalities. The drug has also received "orphan drug" designation. Defibrotide was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. It was approved for sale in the United States by the U.S. Food and Drug Administration (FDA) on March 30, 2016.

The recommended dose of defibrotide (also called defibrotide sodium) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days. Must be diluted before infusion.

Defibrotide is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for the prevention and treatment of hepatic veno-occlusive disease after HSCT. Due to issues with the mechanism of action of defibrotide, it is necessary to ensure that the patient has not experienced clinically significant bleeding and is hemodynamically stable to no more than one vasopressor before administering defibrotide, and that it should not be co-administered with other intravenous drugs in the same intravenous line at the same time.

The most common side effects (incidence ≥10% and independent causal relationship) with treatment with defibrotide (also called defibrotide sodium) are hypotension, diarrhea, vomiting, nausea, and epistaxis. The incidence of grade 3-4 reactions related to defibrotide was 7%, mainly hypotension, pulmonary and gastrointestinal bleeding, and abdominal cramps. Only 4% of patients discontinued treatment due to side effects.

The above is the introduction of the drug (also called defibrinated sodium), I hope it can help you!

Recommended related hot articles: /newsDetail/84582.html